The annual 10-day competition is held to raise awareness of the Burmese python, an invasive snake, and the damage it has ...

Understaffing costs N.H. Department of Corrections almost $11 million in overtime The department’s vacancy rate is more than 40 percent, and most corrections officers are working about three ...

N.H. ranked first in nation for overall child well-being, per new report But local health experts warned budget cuts and policy changes including to Medicaid could erode the state’s standing ...

Florida python hunterrs, Zach Hoffman, Jan Gianello and Justice Sargood caught a massive Burmese python in the Everglades on May 31, 2025.

As the Trump administration moves to limit COVID booster vaccines for some, here's what to know about the latest variant NB.1.8.1 and its symptoms.

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The stock lost 24% as of market close on Friday. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly. Recursion revealed disappointing first-quarter earnings ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Monday reported a loss of $202.5 million in its first quarter.

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its first-quarter earnings call. RXRX expects several data readouts throughout 2025.

Trump administration officials are ramping up pressure on immigrants to leave the United States of their own volition, or “self deport,” as the number of people the government is deporting ...

Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ: RXRX). The company has emerged as a ...